Please assess the completion status of the following clinical trial:

Trial Title: Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence~* Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5~* Smokes at least 20 cigarettes per day (1 pack per day)~* Expired breath CO level \> 10 ppm and cotinine level \> 210 ng/ml at the baseline measurement~* Currently taking a stable dose of antipsychotic~* Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation~Exclusion Criteria:~* Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month~* History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)~* Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern (e.g., a history of severe heart, liver, or kidney disease or diabetes mellitus)~* Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)~* Currently taking diabetes mellitus medications, St. John's Wort, appetite suppressants, ephedrine-containing medications, theophylline, clonidine, reserpine, methyldopa, or anti-anginal medications (e.g., beta-blockers, calcium channel blockers, nitroglycerin preparations)~* History of schizoaffective disorder and not stabilized on a mood stabilizer (e.g., lithium, valproate, carbamazepine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Nicotine Patch + Bupropion
- 2 (Type: PLACEBO_COMPARATOR): Nicotine patch + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).